• Willing and able to give written informed consent for participation in the trial and able to comply with all trial procedures and requirements.

• Male or female participant aged 40 to 70 years, inclusive, at the screening visit.

• Women of childbearing potential must practice abstinence from heterosexual intercourse or must agree to use a highly effective method of contraception.

⁃ Cohort-specific inclusion criteria:

⁃ Cohort 1, STEMI high-risk patients:

• NT-proBNP \>500 pg/mL within 48 hrs after PCI

• Post-PCI Thrombolysis In Myocardial Infarction (TIMI) score \<3.

• No previous history of coronary artery disease or heart failure.

⁃ Cohort 2, STEMI low-risk patients

• NT-proBNP \<500 pg/mL within 48 hrs after PCI

• Post-PCI TIMI score 3.

• No previous history of coronary artery disease or heart failure.

⁃ Cohort 3 (HFpEF patients)

• Presence of signs and symptoms of HF

• Ejection Fraction ≥50%

• Elevated levels of natriuretic peptides (NT-proBNP≥125pg/mL)

• At least one of the following:

• Relevant structural heart disease (left ventricular hypertrophy or left atrial enlargement)

• Diastolic dysfunction

⁃ Cohort 4 (healthy participants)

• Individuals with no history of coronary disease or heart failure.

• Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator.